John Muir Health logo
  • Patients
    About MyChart
    Locating Patients
    Medicare
    New Patients
    Payment & Insurance
    Physician Open Payments Notice
    Preparing for Surgery
    Pre-Register for a Visit
    Registration & Forms
    Request a Health Record
    Security Center
    Video Visits
    Why Choose Us
  • Services
    Addiction Medicine
    Behavioral Health
    Cancer
    Cardiovascular Services
    Digestive Health
    Emergency Services
    Lab Services
    Medical Imaging
    Neurosciences
    Orthopedics
    Pediatrics
    Physical Rehabilitation
    Pregnancy & New Parent
    Primary Care
    Urgent Care
    ALL SERVICES
  • Education
    Classes, Screenings & Support Groups
    Clinical Trials
    Conditions & Treatments
    Health & Wellness
  • Health Professionals
    Careers
    Clinical Research
    Family Medicine Residency Program
    John Muir Medical Group
    Medical Staff
    Nursing
    Pharmacy Residency Program
    Resources
    Training & Education
    Video & Publication Center
  • About Us
    Annual Reports
    Awards & Recognition
    Board of Directors
    Community Commitment
    Employers, Brokers, & Health Plans
    Executive Team
    Make a Gift
    Mission & Vision
    Partnerships
    Media Center
MyChart Login
  • Find a location
  • Find a doctor
  • Pay a bill
  • Find a job
✕

Latest information on COVID-19 >

  1. Home
  2. About Us
  3. Media Center
  4. Press Releases
  5. John Muir Health among First Hospitals in Northern California to Offer Breakthrough Device for Patients with Debilitating Heart Valve Disease

John Muir Health among First Hospitals in Northern California to Offer Breakthrough Device for Patients with Debilitating Heart Valve Disease


Minimally Invasive MitraClip Improves Quality of Life for Patients at High Risk for Open Heart Surgery

Concord, Calif. (July 20, 2015) – Physicians at John Muir Health are among the first in Northern California to offer patients suffering from mitral regurgitation (MR), a breakthrough new minimally invasive treatment option. Performed at John Muir Medical Center, Concord, percutaneous mitral valve repair, or MitraClip, has been approved for U.S. patients with severe symptomatic degenerative MR who are at prohibitive risk for open heart, mitral valve surgery. Physicians at John Muir Health successfully performed their first MitraClip procedure on June 11 and have a number of procedures slated in the coming weeks.

Degenerative MR is caused by an anatomic defect of the mitral valve of the heart. It's a debilitating, progressive and life-threatening disease in which a leaky mitral valve causes a backward flow of blood in the heart. MR is common, affecting more than 4 million Americans – nearly one in 10 people aged 75 and above. The condition can raise the risk of irregular heartbeats, stroke, and heart failure.

Open heart mitral valve surgery is the gold standard treatment, but many patients are at prohibitive risk for the invasive procedure based on certain factors, such as age and physical condition. Medications for the condition are limited to symptom management and do not stop the progression of the disease.

Abbott Vascular's MitraClip procedure repairs the mitral valve without the need for open heart surgery. The device is delivered to the heart through the femoral vein, a blood vessel in the leg, and once implanted, allows the heart to pump blood more efficiently, thereby relieving symptoms and improving patient quality of life. Patients undergoing MitraClip treatment typically experience short recovery times and short hospital stays, which are generally less than 48 hours.

The John Muir Health MitraClip team is comprised of cardiologists and cardiovascular surgeons, who work closely together to screen and perform the MitraClip procedure on those patients that will benefit greatly from this life-enhancing treatment. They include cardiologists Andrew Dublin, M.D., Faizul Haque, M.D., Paul McWhirter, M.D., Howard Min, M.D. and Perkin Shiu, M.D. and cardiovascular surgeons Murali Dharan, M.D. and Jatinder Dhillon, M.D.

Multiple trials, published reports, and registries of patients treated with the MitraClip device consistently demonstrate its safety, reduction in MR, improvement in symptoms, and reduction in hospitalizations for heart failure, even in some of the most severely ill and debilitated patients. More than 20,000 patients around the world have been treated with the MitraClip device.

Related Links
  • About Us
  • Contact Us
Hi! I'm here to help answer your questions.
Chat
ABOUT
About Us
Board of Directors
Executive Team
Awards & Recognition
Partnerships
Community Commitment
Employers, Brokers & Health Plans
NEWS & PRESS
Media Center
Annual Reports
GET INVOLVED
Careers
Volunteer
Make a Gift
CONTACT
Email Us
PRIVACY
Patient Privacy
Website Privacy
Terms of Use
Security Center
Follow Us

© John Muir Health All rights reserved.

John Muir Health is accredited by The Joint Commission. 

We use cookies to measure website traffic and personalize content for a better browsing experience. By using this website, you consent to our cookies. For more details, see our Website Privacy Policy.